Novartis AG (NVS)
161.40
+9.34
(+6.14%)
USD |
NYSE |
Sep 01, 12:01
Novartis Cash from Operations (TTM) : 18.41B for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 18.41B |
| March 31, 2026 | 19.29B |
| December 31, 2025 | 19.24B |
| September 30, 2025 | 21.18B |
| June 30, 2025 | 20.89B |
| March 31, 2025 | 19.00B |
| December 31, 2024 | 17.62B |
| September 30, 2024 | 15.97B |
| June 30, 2024 | 15.06B |
| March 31, 2024 | 13.77B |
| December 31, 2023 | 14.46B |
| September 30, 2023 | 16.05B |
| June 30, 2023 | 15.40B |
| March 31, 2023 | 15.58B |
| December 31, 2022 | 14.26B |
| September 30, 2022 | 14.02B |
| June 30, 2022 | 14.21B |
| March 31, 2022 | 14.59B |
| December 31, 2021 | 15.07B |
| September 30, 2021 | 15.27B |
| June 30, 2021 | 13.50B |
| March 31, 2021 | 13.33B |
| December 31, 2020 | 13.73B |
| September 30, 2020 | 13.18B |
| June 30, 2020 | 14.59B |
| Date | Value |
|---|---|
| March 31, 2020 | 13.74B |
| December 31, 2019 | 13.62B |
| September 30, 2019 | 13.83B |
| June 30, 2019 | 13.36B |
| March 31, 2019 | 14.19B |
| December 31, 2018 | 14.30B |
| September 30, 2018 | 13.99B |
| June 30, 2018 | 13.49B |
| March 31, 2018 | 13.13B |
| December 31, 2017 | 12.65B |
| September 30, 2017 | 12.80B |
| June 30, 2017 | 12.45B |
| March 31, 2017 | 11.98B |
| December 31, 2016 | 11.48B |
| September 30, 2016 | 12.04B |
| June 30, 2016 | 11.94B |
| March 31, 2016 | 11.74B |
| December 31, 2015 | 11.90B |
| September 30, 2015 | 12.94B |
| June 30, 2015 | 13.75B |
| March 31, 2015 | 14.23B |
| December 31, 2014 | 13.90B |
| September 30, 2014 | 13.17B |
| June 30, 2014 | 13.64B |
| March 31, 2014 | 12.76B |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Roche Holding AG | 23.75B |
| AstraZeneca PLC | 14.54B |
| Johnson & Johnson | 27.61B |
| Eli Lilly & Co. | 28.08B |
| Merck & Co., Inc. | 19.97B |